This bundle combines retatrutide and cagrilintide, two compounds individually studied for weight management through different receptor pathways. As of 2026 no published trial has tested the two combined, despite the pairing's popularity in online discussion.
What's in this bundle
Combines Retatrutide and Cagrilintide. Important distinction: Cagrilintide's real combination-trial data (the "CagriSema" program) pairs it with semaglutide, not retatrutide — no published trial has tested cagrilintide combined with retatrutide specifically. Both compounds have strong individual trial data on their own pages, but this specific pairing is unstudied.
Has Retatrutide plus Cagrilintide been tested together in a trial?+
No published trial has tested this specific combination as of 2026. The closest analog, REDEFINE 1, paired cagrilintide with semaglutide (not retatrutide) and reported 22.7% mean weight loss at 68 weeks.
Are Retatrutide and Cagrilintide individually FDA-approved?+
No. Retatrutide is investigational; cagrilintide is approved only in the combination product CagriSema (with semaglutide), not as a standalone.
Can I read about each compound individually?+
Yes, Retatrutide and Cagrilintide each have their own dedicated page on this site with a full research overview and FAQ.
Why combine two weight-management compounds anyway?+
They work through different receptor pathways — Retatrutide is a triple agonist (GLP-1/GIP/glucagon), Cagrilintide works through amylin signaling. Distinct mechanisms should add rather than overlap, even without a dedicated trial confirming it for this exact pair.
Looking for something specific, or placing a wholesale order? Send us a DM or email.